Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Nanoparticle Therapy Reduces Plaque Inflammation and Lowers Risk of Heart Attack or Stroke

By BiotechDaily International staff writers
Posted on 06 Feb 2014
Image: A novel HDL nanoparticle (red) loaded with a statin drug, specifically targets and locally treats inflammatory macrophage cells (green) hiding inside high-risk plaque within blood vessels (Photo courtesy of Mount Sinai Medical Center).
Image: A novel HDL nanoparticle (red) loaded with a statin drug, specifically targets and locally treats inflammatory macrophage cells (green) hiding inside high-risk plaque within blood vessels (Photo courtesy of Mount Sinai Medical Center).
Reconstituted HDL (high-density lipoprotein) nanoparticles were used to transport inflammation-retarding statins to atherosclerotic plaques where the drug acted to reduce arterial blockage that could cause heart attack or stroke.

Inflammation is a key feature of atherosclerosis and a target for therapy. While statins are known to have potent anti-inflammatory properties, they cannot be exploited fully as an oral statin therapy due to low systemic bioavailability.

Investigators at Mount Sinai School of Medicine (New York, NY, USA) sought to concentrate the anti-inflammatory benefits of statins by incorporating them into nanoparticles that would accumulate at sites of inflammation within the blood vessels. For this purpose, they designed an injectable reconstituted high-density lipoprotein (rHDL) nanoparticle carrier vehicle capable of delivering statins directly to atherosclerotic plaques.

They reported in the January 20, 2014, online edition of the journal Nature Communications that they had initially demonstrated the anti-inflammatory effect of statin-rHDL in vitro and showed that this effect was mediated through the inhibition of the mevalonate pathway. They also applied statin-rHDL nanoparticles in vivo in an apolipoprotein E-knockout mouse model of atherosclerosis and showed that the nanoparticles accumulated in atherosclerotic lesions in which they directly affected plaque macrophages. Finally, they demonstrated that a three-month low-dose statin-rHDL treatment regimen inhibited plaque inflammation progression, while a one-week high-dose regimen markedly decreased inflammation in advanced atherosclerotic plaques.

“Not only could the HDL nanotherapy potentially avert repeat heart attacks, it may also have the power to reduce recurrent strokes caused by clots in brain arteries, ” said senior author, Dr. Willem Mulder, associate professor of radiology at Mount Sinai School of Medicine. “We envision that a safe and effective HDL nanotherapy could substantially lower cardiovascular events during the critical period of vulnerability after a heart attack or stroke. While we have much more to do to confirm clinical benefit in patients, our study shows how this nanotherapy functions biologically, and how this novel concept could potentially also work in the clinical setting to solve a critical problem. This nanotherapy would be the first of its kind.”

The optimum use for HDL-statin nanotherapy would be by injection following treatment of an arterial clot. The HDL nanoparticle would deliver the statin directly to macrophages that are driving the inflammatory response. “This could potentially and very rapidly stabilize a dangerous situation,” said Dr. Mulder. “In addition, after discharge, patients would continue to use their oral statins to control LDL in their blood.”

Related Links:

Mount Sinai School of Medicine



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.